Dr. Reddy’s Anti-Epileptic Drug
Dr. Reddy’s Laboratories Ltd. said it had launched generic anti-epileptic Vigabatrin powder for oral solution in the U.S. market. While filing to the BSE Dr. Reddy’s said that the product was a generic version of Lundbeck’s Sabril powder for oral solution.
In a statement released by the firm, it said that they had launched Vigabatrin powder for oral solution, USP in 500 milligrams per packet. It noted that Dr. Reddy’s Anti-Epileptic Drug was launched after getting approval by the U.S. Food and Drug Administration (FDA).
According to IMS Health data, Sabril brand and generic had U.S. sales of around $274 million (about Rs 1,900 crore) MAT in the previous year.
Sabril is considered as adjunctive therapy for adults and pediatric patients of 10 years of age and older. It is administered to patients who have inadequately responded to various alternative treatments and for whom the potential benefits of the drug outweigh the risk of vision loss.
Shares of Dr. Reddy’s Laboratories increased by 1.77% and closed at Rs 2,554.90 per scrip on the BSE.
About Dr. Reddy’s Laboratories Ltd.- The developer of the Anti-Epileptic Drug
‘Good Health’ is always Dr. Reddy’s Laboratories goal. They see medicines
not just as molecules, but as a means to help patients regain their health. As a leader in the pharmaceutical industry, Dr. Reddy’s Laboratories Ltd realize their unique role; they have the ethical and moral imperative to ensure good health can be delivered to those who need it, and to promote wellness among them.Author: Rahul Mishra
